Kornimate/medical-research-clean huggingface dataset:
cataract surgery technique and ocular clarity

Conditions: Cataract

Summary: the goal of this study is to study the restoration of quality of vision, expressed as straylight, in the immediate period after cataract surgery with two different phacoemulsification technologies.

cataract is an opacification of the lens. with cataract surgery, the lens is surgically removed after which a clear artificial intraocular lens is implanted. for patients, it is important that they regain functional vision as quickly as possible after surgery as a limited vision may increase the risk of falling and increases the dependency on other people. surgical removal of the lens is done with a phacoemulsification system. differences between phacoemulsification systems are the used pump type, the way the needle oscillates, and the fluid dynamics of the system. it is unknown whether any of the available systems offer an advantage on the amount of corneal oedema that develops after surgery and, therefore, results in a more rapid restoration of functional vision.

Eligibility criteria:
inclusion criteria: * diagnosis of cataract in both eyes, * having consented to and is planned to undergo cataract surgery in both eyes, * planned for implantation of a non-toric monofocal intraocular lens (iol) in both eyes, * a targeted refractive error of emmetropia, * corneal astigmatism of ≤1.5 d, * age of at least 18 years, * willing and able to participate in both preoperative and postoperative examinations, and * agreeing to sign the informed consent form. exclusion criteria: * insufficient understanding of the dutch language to comply with study procedures, * any comorbidity (other than cataract) that may significantly affect visual function and/or increase straylight and/or prolong visual recovery after surgery, such as significant macular degeneration, significant glaucoma, significant diabetic eye disease, significant ocular surface disease, cornea dystrophy, corneal opacification, significant vitreous opacities (such as asteroid hyalosis and clinically significant floaters), and history of cerebral vascular accident, * subjects with a history of ocular surgery (e.g., corneal refractive surgery), * subjects with an increased risk of complicated cataract surgery: * lens subluxation or (phaco)iridodonesis, * cataract brunescens, cataract rubra, cataract nigrans, or posterior polar cataract, and * history of ocular trauma, * unability to be (reliably) measured with the c-quant straylight meter or pentacam corneal topographer, and * a calculated iol power in any eye that prohibits implantation of the same type of iol in both eyes.

Keywords: straylight phacoemulsification cataract
vitamin c supplementation as a preventive treatment of diabetic peripheral neuropathy

Conditions: Diabetic Neuropathies

Summary: the purpose of this pilot study is to determine whether vitamin c supplementation is beneficial in treating and/or preventing diabetic peripheral neuropathy in people with type 2 diabetes.

painful diabetic peripheral neuropathy (dpn), a condition characterized by pain affecting the feet, legs and hands that is often characterized as burning or a "pins and needles" sensation, is estimated to affect up to 66% of the u.s. diabetic population. this pilot study will examine the effect of a daily dose of ascorbic acid, a known aldose reductase inhibitor, versus placebo, and the effect that it can have on intracellular erythrocyte (red blood cell) sorbitol levels, aldose reductase activity and aldose reductase enzyme levels utilizing benchtop methods, and effects on clinical dpn-associated pain reporting and changes in quantitative sensory testing in the lower extremities via touch discrimination and vibratory sensory testing in patients with type 2 diabetes mellitus (t2dm) over the course of 90 days of treatment.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * diabetic peripheral neuropathy * a1c of 6.0-10.0% exclusion criteria: * terminal diagnosis * dementia * anemia * significant renal dysfunction * history of b-12 deficiency * peripheral vascular disease * current smoker * history of kidney stones * current ascorbic acid use * presence or foot infection and/or ulcer

Keywords: vitamin c ascorbic acid diabetic neuropathies
effect of post-stroke discharge training

Conditions: Stroke; Caregiver Burnout

Summary: the aim of this study was to determine the effect of post-stroke discharge training and telephone counseling service on patients' functional status and caregiver burden. the study was conducted with 69 stroke patients (34 in the intervention group and 35 in the control group) and their caregivers. in the study, data were collected before discharge and three months after discharge. discharge training and telephone counseling (one week after discharge and once a month for three months) were given to the caregivers of the patients in the intervention group.

this study, which was planned as a randomised controlled study, was conducted university hospital neurology clinic in turkey. a total of 80 participants who met the inclusion criteria were randomised to either the intervention and control groups. in this study, patient information form, modified rankin scale and barthel index were used to collect data about patients, while caregiver information form and caregiver burden scale were used to collect data about caregivers pre-tests were applied to patients and caregivers in the intervention and control groups before discharge. after the pre-tests were applied to the caregivers in the intervention group, discharge training was given.

Eligibility criteria:
inclusion criteria: * the age of 18 and over (for patients and caregivers) * having undergone a hemorrhagic or ischemic stroke (for patients) * being literate (for caregivers) * being primarily responsible for the care of the stroke patient during the hospital stay and at home after discharge (for caregivers) * using a mobile or home phone (for caregivers) * being open to communication and collaboration (for caregivers) exclusion criteria: * rankin scale score of 4 above (for patients) * having problem in terms of hearing and understanding (for caregivers)
scanbrit dietary intervention in autism

Conditions: Autism; Autism Spectrum Disorder (ASD)

Summary: a growing body of research indicates that dietary intervention excluding foods containing the proteins, gluten and casein, from the diet of children diagnosed with an autism spectrum disorder (asd) may have a positive effect on behaviour and developmental outcome. in this single-blind, randomised-controlled, matched-pair adaptive trial, we introduced a gluten- and casein-free (gfcf) diet to a group of pre-pubescent children diagnosed with asd concurrently with an abnormal urinary profile. following random allocation to a diet or non- diet group, stage 1 of the study saw an intervention group follow the gfcf diet for eight months initially - progressing to 12 months if required. a non-diet control group continued with a normal diet. assuming significant changes for the dietary group on the various outcome measures of behaviour and development, stage 2 of the study saw both groups assigned to gfcf dietary intervention for a further 12 months when outcome measures were again assessed at study end.

eligibility criteria: diagnosis of autism, no co-morbid diagnosis of fragile x syndrome, epilepsy or tuberous sclerosis, aged between 4-10y11m. experimental hypothesis: children with an autism spectrum disorder (asd) on a gfcf diet would show a significantly improved group developmental outcome in the medium- and long-term with regards to core autism and/or secondary symptoms. main outcome measures: change in scores of dietary participants on one or more measures against predefined statistical thresholds as evidence of improvement, alongside changes to intra- and inter-group scores at study endpoint. main outcome measures ascertained by: autism diagnostic observation schedule (ados), gillam autism rating scale (gars), vineland adaptive behaviour scales (vabs), attention deficit hyperactivity disorder - iv (adhd-iv) scales.

Eligibility criteria:
inclusion criteria: * autism spectrum disorder (asd) * diagnosis received at centre for autism or a psychiatric clinic * abnormal urinary peptide profile exclusion criteria: * medical treatment * epilepsy

Keywords: autism autism spectrum disorder diet gluten casein intervention peptide randomised controlled adaptive design autism diagnostic observation schedule (ados) gilliam autism rating scale (gars) vineland adaptive behaviour scale (vabs) attention-deficit hyperactivity disorder (adhd)-iv scale
quality of life in allergic rhinoconjunctivitis patients treated with dialyzable leukocyte extracts

Conditions: Allergic Rhinoconjunctivitis

Summary: the purpose of this study is to determine the changes of quality of life of patients with allergic rhinoconjunctivitis treated with standard medications plus dialyzable leukocyte extracts (dle). all patients will receive dle in combination with current guide lines-suggested standard medication.

dle are heterogenous mixtures of peptides under 10 kilo daltons (kda) obtained after disruption of peripheral blood leukocytes from healthy human donors. dle have been reported to improve clinical response in allergies, such as asthma and atopic dermatitis. the therapeutic effect of dle is related to an immune modulatory effect that changes innate signaling pathways, such as toll like receptors, and nuclear factor -kappa b; production of cytokines might also be modified with the use of dle, including tumor necrosis factor a, interleukin (il)-6, and induction of interferon-g secretion, driving immune response to a t-helper th1 immune-regulatory response, and thus helping to reduce allergy symptoms.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of symptomatic seasonal or perennial allergic rhinitis * active rhinoconjunctivitis * six week standard treatment before inclusion * confirmation of an immunoglobulin e-mediated response through previous positive skin or in vitro allergen testing exclusion criteria: * other immunological immune-mediated diseases such as autoimmune diseases and cancer. * unstable chronic disease, such as diabetes, cardiac diseases, chronic kidney failure, chronic hepatic disease.

Keywords: allergic rhinoconjunctivitis dialyzable leukocyte extracts
economic navigation and strengthening to research unrestricted services for transgender women (entrust)

Conditions: Transgender Women; Aids; Hiv

Summary: the overall hypothesis is that stabilizing transgender women financially while providing them tailored counselling will increase their odds of them linking to substance use services, prep services if they do not have hiv, and transgender women who are living with hiv will be more adherent to their art treatment.

there continues to be a gap in the extant literature on the relationship between substance abuse and achievement of viral suppression (vs) through adherent antiretroviral treatment (art) or prep uptake among transgender women which warrants further investigation. harmful alcohol and illicit drug use associated with substance use disorders (sud) have been independently linked to condomless sex and hinder engagement in ending the hiv epidemic (ehe) prevention initiatives, including hiv retention in care and adherence to treatment to achieve viral suppression and prep use. transgender women are among the most at risk group of sexually active populations, yet least likely to be aware of and/or use preexposure prophylaxis (prep) to prevent hiv transmission.5 prep and routine hiv/sti screening, are effective approaches to reduce hiv incidence in marginalized at-risk populations and are consistent with the us national hiv/aids strategy.

Eligibility criteria:
inclusion criteria: * aged ≥18 years * male at birth * identify as a woman/transgender woman * should not be consistently using prep (less than four doses per week) * should not have any known allergy or adverse reaction to prep or the active drug tenofovir in art. one of the goals of the study is to move more people into a prep program * be able to speak and understand spoken english and/or spanish (including persons who cannot read or write) * have a smart phone that can take pictures exclusion criteria: * unwilling to adhere to study procedures * participation in an hiv vaccine trial * have a life-threatening sud\* * any condition, that in the opinion of the study staff, would make participation in the study unsafe, or interfere with achieving the study objective such as medical conditions which prevents the use of prep * unable to provide consent
safety and performance of peek anchors in extremities

Conditions: Medial or Lateral Instability Repairs/Reconstructions; Hallux Valgus Repairs; Achilles Tendon Repairs/Reconstructions; Midfoot Reconstructions; Metatarsal Ligament/Tendon Repairs/Reconstructions; Bunionectomy; Scapholunate Ligament Reconstructions; Ulnar; Lateral Epicondylitis Repair; Bicep Tendon Reattachments

Summary: safety and performance of the study devices in extremities up to 12 months post-surgery


Eligibility criteria:
inclusion criteria: * subjects who have undergone extremity joint repair using the study devices. * subjects aged 18 years and older at the time of surgery. exclusion criteria: * subject is entered in another investigational drug, biologic, or device study or has been treated with an investigational product within 12 months post-operative. * subjects who are \< 3 months post-operative

Keywords: dynomite spyromite raptormite foot ankle wrist hand elbow footprint
sars-cov-2 screening in dialysis facilities

Conditions: End-stage Renal Disease; SARS-CoV-2 Acute Respiratory Disease; Dialysis; Complications

Summary: patients receiving dialysis are one of the highest risk groups for serious illness with sars-cov-2 infection. in addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. in this pragmatic cluster randomized controlled trial as part of nih radx-up consortium, we will randomize 62 us renal care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. static universal screening will involve offering patients sars-cov-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community covid-19 case rates. we hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of covid-19 death and hospitalization, and report better experience-of-care metrics.


Eligibility criteria:
inclusion criteria: * facility * an established us renal care in-center hemodialysis facility located in a county with at least two us renal care facilities * facility governing board (medical director, facility manager, social worker and charge nurses) willingness to participate patient * treatment at us renal care in-center hemodialysis facility * age ≥ 18 years exclusion criteria: * patient * unwillingness to share anonymized clinical (electronic health record) or serum samples drawn during routine dialysis care (i.e., without an additional needlestick). if a patient declines offered testing he/she will still be part of the analyses as long as he/she is willing to share clinical data * dementia or cognitive impairment, with inability to comprehend 'opting out' of participation

Keywords: screening underserved communities radx-up
chronic abdominal pain after gastric bypass

Conditions: Abdominal Pain

Summary: the study aims to explore patients perception of chronic abdominal pain after roux en y gastric bypass surgery for morbid obesity. the investigators aim to describe characteristics of symptoms of pain. potential risk factors for developing abdominal pain post gastric bypass will be explored.

this is a single-center, prospective, longitudinal, cohort study performed at the department of morbid obesity and bariatric surgery, oslo university hospital. patients undergoing gastric bypass are eligible for inclusion. the study is approved by the regional committee for medical and health research ethics (no.2013/1263), south-east health region. all participants provide written consent for study paennrollment. the participants are asked to fill inn a set of questionnaires before and during follow-up after gastric bypass surgery. symptom characteristics are explored and evaluated. quality of life is included in the analyses. the main outcome is findings at 2 years post surgery, but the patients will be followed for 5 years. the investigators also aim to evaluate by objective measures the patients perception of pain by temperature and skin pressure stimulants before and after surgery (2 years).

Eligibility criteria:
inclusion criteria: • indication for gastric bypass surgery i.e. bmi \> 40 kg/m2 or bmi \> 35 kg/m2 and obesity related comorbidity following failed attempts of sustained weight loss exclusion criteria: * other indications for gastric bypass surgery than obesity * previous bariatric surgery * other concomitant surgical procedures for abdominal pain such as cholecystectomy

Keywords: morbid obesity gastric bypass pain symptoms
effects of sodium pentaborat based gel on perianal benign diseases

Conditions: Hemorrhoids; Anal Fissure; Perianal Fistula

Summary: new produced and patented sodium pantaborat based gel will be use for treatment of benign perianal diseases (hemooroidal disease, anal fissura anda perianal fistula)

prospective randomised clinical trial planned. older than 18 years old perianal benign diseases (grade 1 and 2 hemorroidal disease, anal fissura, uncomplicated simple perianal fistula) cases without malign tumour, cronic colorectal disases, and routine used of vasoactive medication cases were entered the study. younger than 18 years old, diagnosed any malign tumor and/or cronic colorectal disaeses, routine used of vasoact,ve mediaction cases were exclused of the study. group-1 (n: 50): healthy cases (control group) group-2 (n:50): grade 1 hemorroidal disease cases group-3 (n:50): grade 2 hemorroidal disease cases group-4 (n:50): anal fissure cases group-5 (n:50): uncomplicated, simple perianal fistula cases

Eligibility criteria:
inclusion criteria: * grade 1 and 2 hemorroidal disease * cronic anal fissura * uncomplicated simple perianal fistula exclusion criteria: * any malign tumour * cronic colorectal disases * routine used of vasoactive medication
israeli biologic lung volume reduction (blvr) phase 1 emphysema study

Conditions: Pulmonary Emphysema; Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate the safety and efficacy of the biologic lung volume reduction system (blvr) for patients with advanced emphysema refractory to medical therapy.

background: patients with emphysema currently have limited treatment choices. many patients are treated with steroids and inhaled medications, which often provide little or no benefit. in recent years, lung volume reduction surgery has become an accepted therapy for advanced emphysema. lung volume reduction surgery involves the removal of diseased portions of the lung in order to enable the remaining, healthier portions of the lung to function better. this procedure, although effective for many patients, is complicated and is accompanied by substantial morbidity and mortality risk. aeris therapeutics has developed the biologic lung volume reduction (blvr) system which is intended to achieve lung volume reduction without surgery and its attendant risks. patients are treated using a bronchoscope to direct treatment to the most damaged areas of the lung. the treatment delivers a precisely proportioned proprietary mixture of drugs and biologics which, when combined at the treatment site, form a biodegradable hydrogel. the hydrogel acts to reduce lung volume by permanently collapsing and sealing the diseased areas of the lung. this provides room within the chest to allow the remaining healthier portions of the lung to function better. aeris' blvr development program has been granted fast track designation by the u.s. fda, and is the subject of ongoing clinical trials designed to investigate the safety and efficacy of the blvr system as a treatment for patients with advanced heterogeneous emphysema. fast track designation is reserved for drug and biologic development programs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of advanced emphysema * age \>/= 40 years * clinically significant dyspnea * failure of standard medical therapy to relieve symptoms (inhaled beta agonist \& inhaled anticholinergic) * pulmonary function tests within protocol-specified ranges (post bronchodilator fev1 \ 110% predicted; residual volume \> 150% predicted) * 6 minute walk distance \>/= 150 m exclusion criteria: * alpha-1 protease inhibitor deficiency * tobacco use within 4 months of initial visit * body mass index \ 35 kg/m2 * clinically significant asthma, chronic bronchitis or bronchiectasis * allergy or sensitivity to procedural components * pregnant, lactating or unwilling to use birth control if required * prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endotracheal valve placement, airway stent placement or pleurodesis * comorbid condition that could adversely influence outcomes * significant comorbidity

Keywords: lung volume reduction bronchoscopy emphysema copd nett lung disease cold blvr